about
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. ...
Read More
41.63
2.27
(5.77%)
6.9M
XNAS Volume
XNAS 16 Jan, 2026 12:26 PM (EST)
Low Financial Strength
Expensive Valuation
Technically Moderately Bullish
Momentum Trap
These stocks have weak financials and expensive valuation. Buying interest may quickly dissipate. Investors should exercise caution
View Similar
Embed DVM
Moderna Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..